SEC Form 4 · accession 0000950138-18-000299
Keenova Therapeutics plc
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Frank Scholz
Officer — EVP Glob Ops & Pres Spec Gen
Period of report
Apr 2, 2018
Accepted (ET)
Apr 4, 2018 · 5:51 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001567892
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1,F2 | Apr 2, 2018 | A | 31,885 | $0.00 | A | 74,141 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Share Options (Right to Buy)F3 | $13.80 | Apr 2, 2018 | A | 166,497 | A | Apr 2, 2019 | Apr 2, 2028 | Ordinary Shares | 166,497 | 166,497 | D |
Explanation of responses
- F1Represents restricted stock units that vest in four equal annual installments beginning April 2, 2019.
- F2Includes 1,062 shares acquired on March 31, 2018 under the Mallinckrodt employee stock purchase plan.
- F3The options vest in four equal annual installments beginning April 2, 2019.